Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study-Reference-Cited by-同舟云学术

Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study

Published:2022-01-05 Issue:5 Volume:23 Page:629-638
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Garcia-Portilla Maria Paz¹^ORCID,Benito Ruiz Adolfo²,Gómez Robina Felisa³,García Dorado Marta⁴,López Rengel Paola María⁴

Affiliation:

1. Department of Psychiatry, University of Oviedo, CIBERSAM, Oviedo, Spain

2. Psychiatry Service, University Hospital Complex of Toledo, Toledo, Spain

3. Psychiatry Service, Santa Teresa Hospital, Ávila, Spain

4. Medical Department, Janssen Cilag, Madrid, Spain

Funder

Janssen-Cilag S.A

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2021.2023496

Reference43 articles.

1. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia

2. Remission in Schizophrenia: Critical and Systematic Review

3. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database;Neuropsychopharmacology Reports;2024-09-11

2. Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia;JAMA Network Open;2024-07-17

3. Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study;Neuropsychiatric Disease and Treatment;2023-04

4. The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia;Neuropsychiatric Disease and Treatment;2023-03